Industry welcomes EU moves to improve orphan drug access
This article was originally published in Scrip
Executive Summary
The biopharmaceutical industry has welcomed moves by the European Commission to set up a new EU rare diseases expert committee with industry representation, and has given its backing to calls for a new body to be established at the European Medicines Agency to assess the added value represented by new orphan drugs.
You may also be interested in...
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.